adapalene has been researched along with ketoconazole in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Ren, XK; Shi, TW; Tang, YB; Yu, HX | 1 |
| Li, ZG; Shi, TW; Tang, YB; Yu, HX; Yu, JB; Zhang, JA | 1 |
| Abd-Elaziz, H; Abd-Elrazek, H; Abdo, H; Amer, M; Bakr, E | 1 |
3 trial(s) available for adapalene and ketoconazole
| Article | Year |
|---|---|
Roles of adapalene in the treatment of pityriasis versicolor.
Topics: Adapalene; Adult; Dermatologic Agents; Female; Gels; Humans; Ketoconazole; Male; Middle Aged; Naphthalenes; Tinea Versicolor; Treatment Outcome | 2012 |
A randomized controlled trial of combination treatment with ketoconazole 2% cream and adapalene 0.1% gel in pityriasis versicolor.
Topics: Adapalene; Adult; Drug Therapy, Combination; Female; Humans; Ketoconazole; Male; Tinea Versicolor; Young Adult | 2015 |
Adapalene gel 0.1% vs ketoconazole cream 2% and their combination in treatment of pityriasis versicolor: A randomized clinical study.
Topics: Acne Vulgaris; Adapalene; Dermatologic Agents; Gels; Humans; Ketoconazole; Ointments; Tinea Versicolor; Treatment Outcome | 2020 |
2 other study(ies) available for adapalene and ketoconazole
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |